ZURICH/BERLIN, March 11 (Reuters) - The Swiss blue-chip SMI was seen opening 0.33 percent higher at 9,299 points on Monday, according to premarket indications by bank Julius Baer .
Here are some of the main factors that may affect Swiss stocks:
The Swiss medical device maker said on Monday it plans an initial share sale, taking advantage of a rising Swiss stock exchange that has added 10 percent this year to its benchmark index as the implant maker seeks to boost its visibility by going public.
The Swiss lender and Standard Chartered PLC have agreed to settle a case of alleged misconduct related to a 2009 initial public offering (IPO) in Hong Kong, a counsel for the market regulator said at a tribunal hearing on Monday.
The Swiss company won U.S. approval on Friday of its immunotherapy Tecentriq to treat a significant number of patients with triple-negative breast cancer, a development hailed by doctors as a promising advance in fighting the aggressive disease.
*Tornos Holding said its full-year net result was up 86 percent in fiscal 2018, at 15.3 million Swiss francs ($15.17 million).
*Tecan Group said its full-year net profit in fiscal 2018 amounted to 70.7 million Swiss francs, adding that sales in 2019 were forecast to increase in a mid- to high single-digit percentage.
*Schweiter Technologies AG said it proposed a dividend of 40 Swiss francs per bearer share after net profit from continuing operations declined to 77 million from 60.3 million Swiss francs.
* Belimo said full-year net income rose by 11.3 percent to 86.2 million francs.
No major Swiss economic data scheduled ($1 = 1.0083 Swiss francs) (Reporting by Zurich newsroom and Berlin Speed Desk)